Unlock instant, AI-driven research and patent intelligence for your innovation.

A kind of compound antihypertensive preparation and application thereof

A technology of inhibitors and high blood pressure, applied in the field of medicine, can solve the problems of target organ protection not being correspondingly enhanced, angioneural edema, abnormal blood potassium, etc., to reduce the probability of abnormal blood potassium, enhance the protective effect, Strengthen the effect of synergistic antihypertensive effect

Active Publication Date: 2018-10-26
XIAN HANFENG PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Clinically, the compound drug composed of low-dose thiazide diuretics such as hydrochlorothiazide and ACEI has outstanding synergistic antihypertensive performance, and ACEI can also inhibit the renin-angiotensin system (RAS) activation and Partially offset the side effects of hypokalemia, but long-term use may still cause problems such as cough, abnormal blood potassium, and vascular nerve edema
In addition, the protective effect of such compounds on target organs has not been correspondingly enhanced, on the contrary, it may be weakened due to the influence on lipid metabolism

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of compound antihypertensive preparation and application thereof
  • A kind of compound antihypertensive preparation and application thereof
  • A kind of compound antihypertensive preparation and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0036] Embodiment 1: the preparation of compound pharmaceutical composition 1 (tablet) (in 1000 pieces)

[0037]

[0038] Preparation:

[0039] Pass enalapril and metofazone in the prescribed amount through an 80-mesh sieve; pass lactose, microcrystalline cellulose, pregelatinized starch, and sodium carboxymethyl starch through a 60-mesh sieve, and mix them evenly by an equal-volume increasing method. Add 50% ethanol to make soft material, granulate with 18-mesh sieve, dry the wet granules at 40°C, and granulate with 18-mesh sieve. Add magnesium stearate and mix well. Detect the content of semi-finished products, calculate the tablet weight, press the tablet machine, and store it in the dark. Each of the prepared compound tablets contains 10 mg of enalapril and 0.5 mg of metofazone.

Embodiment 2

[0040] Example 2: Preparation of Compound Pharmaceutical Composition 2 (tablets) (calculated in 1000 tablets)

[0041]

[0042]

[0043] Preparation Process:

[0044] Pass the prescribed amounts of enalapril and metofazone through an 80-mesh sieve; pass lactose, microcrystalline cellulose, pregelatinized starch, sodium carboxymethyl starch and calcium hydrogen phosphate through a 60-mesh sieve, and use the equal increment method well mixed. Then add magnesium stearate and mix well. Detect the content of semi-finished products, calculate the tablet weight, press the tablet machine, and store it in the dark. Each of the prepared compound tablets contains 20 mg of enalapril and 0.25 mg of metofazone.

Embodiment 3

[0045] Example 3: Preparation of Compound Pharmaceutical Composition 3 (capsules) (in 1000 capsules)

[0046]

[0047] Preparation Process:

[0048] Pass the main medicine through 80 mesh sieves and the auxiliary materials through 60 mesh sieves respectively, and set aside. Weigh 5g of enalapril and 1g of metofazone and mix them evenly according to the equal increment method. Add lactose, microcrystalline cellulose, crospovidone and sodium lauryl sulfate according to the prescribed amount, respectively, according to the equal increment method. Mix uniformly, add 5% povidone ethanol solution to make soft material, granulate with a 20-mesh sieve, and dry at 40°C. After the granules are dried, sieve with a 20-mesh sieve for granulation, and then add magnesium stearate and mix evenly. The content of semi-finished products is detected, the filling amount is calculated, and the No. 3 capsule is filled. Each capsule contains 5mg enalapril and 1mg metofazone.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a pharmaceutical composition for treating hypertension. The pharmaceutical composition comprises (1) an angiotensin-converting enzyme inhibitor, (2) furosemide metolazone (former name: metolazone), and (3) pharmaceutically acceptable auxiliary materials, wherein the weight ratio of the angiotensin-converting enzyme inhibitor to the metolazone is (10-40) to (0.5-1). By combination of the angiotensin-converting enzyme inhibitor and the metolazone, the synergistic hypotensive action is reinforced; the protection effect on target organs, especially kidneys are enhanced; the probability of serum potassium abnormity is lowered; the compliance of patients is improved; the population of medication is expanded; and the pharmaceutical composition is suitable for severe and intractable hypertension, especially secondary hypertension caused by kidney damages.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a pharmaceutical composition in which angiotensin-converting enzyme inhibitors and metolazone (formerly known as metolazone) are active ingredients and an application thereof. Background technique [0002] Hypertension is one of the most common cardiovascular diseases at present. Inadequate treatment can easily lead to stroke, myocardial infarction, heart failure, chronic kidney disease and other complications, with high disability and fatality rates, consuming a lot of medical resources and social wealth. Bring a great burden to the family and society. Therefore, the main goal of hypertension treatment is to minimize the overall risk of cardiovascular complications and death, and to treat all reversible cardiovascular risk factors, target organ damage, and other coexisting clinical diseases. [0003] Currently, drugs for the treatment of hypertension include calcium channel blockers (C...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K45/06A61K31/517A61K38/05A61K31/55A61P9/12
Inventor 郭树攀陈涛王汝涛
Owner XIAN HANFENG PHARMA